10,000 Re-Randomization Sequences Confirm Simponi Efficacy Results
This article was originally published in Pharmaceutical Approvals Monthly
Centocor demonstrated that an adaptive randomization technique provided comparable results to conventional randomization during pivotal trials for Simponi (golimumab)
You may also be interested in...
FDA's Cardiovascular and Renal Drugs Advisory Committee sided with FDA's more conservative statistical analysis of Boehringer Ingelheim's Micardis, rejecting the company's claim that telmisartan demonstrated non-inferiority to ramipril in a pivotal trial
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011